References
- Maj M. Why the clinical utility of diagnostic categories in psychiatry is intrinsically limited and how we can use new approaches to complement them. World Psychiatry. 2018;17(2):121–122. doi: 10.1002/wps.20512
- Maj M, Stein DJ, Parker G, et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry. 2020;19(3):269–293. doi: 10.1002/wps.20771. PMID: 32931110; PMCID: PMC7491646.
- Guideline Development Panel for the Treatment of Depressive Disorders. APA clinical practice guideline for the treatment of depression across three age cohorts. Washington (DC): American Psychiatric Association; 2019.
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. [2018 Apr 7];391(10128):1357–1366. doi: 10.1016/S0140-6736(17)32802-7
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. doi: 10.1176/ajp.2006.163.11.1905
- Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet. 2007;370(9590):859–877. doi: 10.1016/S0140-6736(07)61238-0
- Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22–27. doi: 10.4088/PCC.v03n0105
- Gaynes BN, Lux L, Gartlehner G, et al. Defining treatment-resistant depression. Depress Anxiety. 2020;37(2):134–145. doi: 10.1002/da.22968
- Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334–385. doi: 10.3109/15622975.2013.804195
- Walsh JK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence- based medicine. Sleep. 2004;27(8):1441–1442. doi: 10.1093/sleep/27.8.1441
- Verdolini N, Perugi G, Samalin L, et al. Aggressiveness in depression: a neglected symptom possibly associated with bipolarity and mixed features. Acta Psychiatr Scand. 2017;136(4):362–372. doi: 10.1111/acps.12777
- Munizza C, Olivieri L, Loreto GD, et al. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2006;22(9):1703–1713. doi: 10.1185/030079906X121039
- Ballerio M, Politi P, Crapanzano C, et al. Clinical effectiveness of parenteral trazodone for the management of psychomotor activation in patients with bipolar disorder. Neuro Endocrinol Lett. 2018;39(3):205–208.
- Bossini L, Coluccia A, Casolaro I, et al. Off-label trazodone prescription: evidence, benefits and risks. Curr Pharm Des. 2015;21(23):3343–3351. doi: 10.2174/1381612821666150619092236
- Carney PA, Healy D, Leonard BE. A double-blind study to compare trazodone with amitriptyline in depressed patients. Psychopathology. 2010;17(Suppl 2):37–38. doi: 10.1159/000284091
- Frecska E. [Trazodone-its multifunctional mechanism of action and clinical use]. Neuropsychopharmacol Hung. 2010;12(4):477–482. Hungarian.
- Karrouri R, Hammani Z, Benjelloun R, et al. Major depressive disorder: validated treatments and future challenges. World J Clin Cases. 2021;9(31):9350–9367. doi: 10.12998/wjcc.v9.i31.9350
- Varghese S, Frey BN, Schneider MA, et al. Functional and cognitive impairment in the first episode of depression: a systematic review. Acta Psychiatr Scand. 2022;145(2):156–185. doi: 10.1111/acps.13385
- Barlati S, Lisoni J, Nibbio G, et al. Current evidence and theories in understanding the relationship between cognition and depression in childhood and adolescence: a narrative review. Diagnostics (Basel). 2022;12(10):2525. doi: 10.3390/diagnostics12102525
- Zacková L, Jáni M, Brázdil M, et al. Cognitive impairment and depression: meta-analysis of structural magnetic resonance imaging studies. NeuroImage Clin. 2021;32:102830. doi: 10.1016/j.nicl.2021.102830
- Bora E, Harrison BJ, Yücel M, et al. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med. 2013;43(10):2017–2026. doi: 10.1017/S0033291712002085
- Matcham F, Simblett SK, Leightley D, et al. The association between persistent cognitive difficulties and depression and functional outcomes in people with major depressive disorder. Psychol Med. 2023;53(13):6334–6344. doi: 10.1017/S0033291722003671
- Rock PL, Roiser JP, Riedel WJ, et al. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2104;44(10):2029–2040. doi: 10.1017/S0033291713002535
- Fried EI, Nesse RM, Gong Q. The impact of individual depressive symptoms on impairment of psychosocial functioning. PLOS One. 2014;9(2):e90311. doi: 10.1371/journal.pone.0090311
- McLennan SN, Mathias JL. The depression-executive dysfunction (DED) syndrome and response to antidepressants: a meta-analytic review. Int J Geriatr Psychiatry. 2010;25(10):933–944. doi: 10.1002/gps.2431
- Maalouf FT, Brent D, Clark L, et al. Neurocognitive impairment in adolescent major depressive disorder: state vs. trait illness markers. J Affect Disord. 2011;133(3):625–632. doi: 10.1016/j.jad.2011.04.041
- McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30(6):515–527. doi: 10.1002/da.22063
- Bartoli F, Carrà G, Biagi E, et al. Agreement between DSM-IV and DSM-5 criteria for alcohol use disorder among outpatients suffering from depressive and anxiety disorders. Am J Addict. 2017;26(1):53–56. doi: 10.1111/ajad.12482
- Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011;106(5):906–914. doi: 10.1111/j.1360-0443.2010.03351.x
- Hunt GE, Malhi GS, Lai HMX, et al. Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: Systematic review and meta-analysis. J Affect Disord. 2020;266:288–304. doi: 10.1016/j.jad.2020.01.141
- Bartoli F, Crocamo C, Biagi E, et al. Clinical utility of a single-item test for DSM-5 alcohol use disorder among outpatients with anxiety and depressive disorders. Drug Alcohol Depend. 2016;165:283–287. doi: 10.1016/j.drugalcdep.2016.06.003
- Boschloo L, Vogelzangs N, van den Brink W, et al. Alcohol use disorders and the course of depressive and anxiety disorders. Br J Psychiatry. 2012;200(6):476–484. doi: 10.1192/bjp.bp.111.097550
- McHugh RK, Weiss RD. Alcohol use disorder and depressive disorders. Alcohol Res. 2019;40(1):arcr.v40.1.01. doi: 10.35946/arcr.v40.1.01
- Nunes EV. Alcohol and the etiology of depression. Am J Psychiatry. 2023;180(3):179–181. doi: 10.1176/appi.ajp.20230004
- Steffen A, Nübel J, Jacobi F, et al. Mental and somatic comorbidity of depression: a comprehensive cross-sectional analysis of 202 diagnosis groups using German nationwide ambulatory claims data. BMC Psychiatry. 2020;20(1):142. doi: 10.1186/s12888-020-02546-8
- Herrman H, Patel V, Kieling C, et al. Time for united action on depression: a Lancet-World Psychiatric Association Commission. Lancet. 2022;399(10328):957–1022. doi: 10.1016/S0140-6736(21)02141-3
- Nordentoft M, Mortensen PB, Pedersen CB. Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry. 2011;68(10):1058–1064. doi: 10.1001/archgenpsychiatry.2011.113
- Dong M, Wang SB, Li Y, et al. Prevalence of suicidal behaviors in patients with major depressive disorder in China: a comprehensive meta-analysis. J Affect Disord. 2018;225:32–39. doi: 10.1016/j.jad.2017.07.043
- Dong M, Zeng LN, Lu L, et al. Prevalence of suicide attempt in individuals with major depressive disorder: a meta-analysis of observational surveys. Psychol Med. 2019;49(10):1691–1704. doi: 10.1017/S0033291718002301
- Fagiolini A, Comandini A, Catena Dell’osso M, et al. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033–1049. Erratum in: CNS Drugs. 2013;27(8):677. doi: 10.1007/s40263-012-0010-5
- Sheehan DV, Croft HA, Gossen ER, et al. Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. Psychiatry. 2009 May;6(5):20–33.
- Fagiolini A, González-Pinto A, Miskowiak KW, et al. Role of trazodone in treatment of major depressive disorder: an update. Ann Gen Psychiatry. 2023;22(1):32. doi: 10.1186/s12991-023-00465-y
- Bartoli F, Bachi B, Callovini T, et al. Anxious distress in people with major depressive episodes: a cross-sectional analysis of clinical correlates. CNS Spectr. 2024 Feb;29(1):49–53. doi: 10.1017/S1092852923002377
- Wichniak A, Jarkiewicz M, Okruszek Ł, et al. Low risk for switch to mania during treatment with sleep promoting antidepressants. Pharmacopsychiatry. 2015 May;48(3):83–88. doi: 10.1055/s-0034-1396802
- Kaynak H, Kaynak D, Gözükırmızı E, et al. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med. 2004;5(1):15–20. doi: 10.1016/j.sleep.2003.06.006
- Shell WE, May LA, Bullias DH, et al. Sentra PM (a medical food) and trazodone in the management of sleep disorders. J Cent Nerv Syst Dis. 2012;4:65–72. doi: 10.4137/JCNSD.S9381
- Doroudgar S, Chou TIF, Yu J, et al. Evaluation of trazodone and quetiapine for insomnia: an observational study in psychiatric inpatients. Prim Care Companion CNS Disord. 2013;15(6):CC.13m01558. doi: 10.4088/PCC.13m01558
- Camargos EF, Louzada LL, Quintas JL, et al. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. 2014;22(12):1565–1574. doi: 10.1016/j.jagp.2013.12.174
- Dudek D, Chrobak AA, Krupa AJ, et al. TED-trazodone effectiveness in depression: a naturalistic study of the effectiveness of trazodone in extended release formulation compared to SSRIs in patients with a major depressive disorder. Front Pharmacol. 2023 Nov 1;14:1296639. doi: 10.3389/fphar.2023.1296639
- Shrashimirova M, Tyanev I, Cubała WJ, et al. Long-term treatment with Trazodone Once-A-Day (TzOAD) in patients with MDD: an observational, prospective study. Neuropsychiatr Dis Treat. 2023 May 12;19:1181–1193. doi: 10.2147/NDT.S399948
- Stein MD, Kurth ME, Sharkey KM, et al. Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial. Drug Alcohol Depend. 2012;120(1–3):65–73. doi: 10.1016/j.drugalcdep.2011.06.026
- Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469–476. doi: 10.4088/JCP.v66n0409
- Pollak CP, Perlick D, Linsner JP, et al. Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health. 1990;15(2):123–135. doi: 10.1007/BF01321316
- Saletu-Zyhlarz GM, Anderer P, Arnold O, et al. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. Neuropsychobiology. 2003;48(4):194–208. doi: 10.1159/000074638
- Raffaele R, Rampello L, Vecchio I, et al. Trazodone therapy of the post-stroke depression. Arch Gerontol Geriatr. 1996;22(Suppl 1):217–220. doi: 10.1016/0167-4943(96)86939-1
- Hamadjida A, Nuara SG, Gourdon JC, et al. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson’s disease. J Neural Transm (Vienna). 2018;125(9):1355–1360. doi: 10.1007/s00702-017-1830-8
- Glass OM, Hermida AP, Hershenberg R, et al. Considerations and current trends in the management of the geriatric patient on a consultation-liaison service. Curr Psychiatry Rep. 2020;22(5):21. doi: 10.1007/s11920-020-01147-2
- Stryjer R, Rosenzcwaig S, Bar F, et al. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. Clin Neuropharmacol. 2010;33(5):219–222. doi: 10.1097/WNF.0b013e3181ee7f63
- Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol. 2009;5(4):210–220. doi: 10.1038/nrneurol.2009.24
- Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55(9):1271–1278. doi: 10.1212/WNL.55.9.1271
- Mendez MF. Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci. 2009;24:168–178. doi: 10.1159/000197896
- Lebert F, Stekke W, Hasenbroekx C, et al. Frontotemporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cognit Disord. 2004;17(4):355–359. doi: 10.1159/000077171
- Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry. 2001;34(4):128–131. doi: 10.1055/s-2001-15871
- Berardis DD, Fornaro M, Ventriglio A, et al. Trazodone add-on in COVID-19-related selective serotonin reuptake inhibitor-resistant post-traumatic stress disorder in healthcare workers: two case reports. Clin Psychopharmacol Neurosci. 2021;19(4):780–785. doi: 10.9758/cpn.2021.19.4.780
- De Filippis S, Lombardozzi G, Matrone M, et al. Differential response to three antidepressants in patients with major depressive episode who suffered Covid-19-related trauma. Curr Neuropharmacol. 2022 Nov 15;20(12):2393–2407. PMID: 35272591; PMCID: PMC9890288]. doi: 10.2174/1570159X20666220310122849
- Culpepper L, Lam RW, McIntyre RS. Cognitive impairment in patients with depression: awareness, assessment, and management. J Clin Psychiatry. 2017;78(9):1383–1394. doi: 10.4088/JCP.tk16043ah5c
- Prado CE, Watt S, Crowe SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol rev. 2018;28(1):32–72. doi: 10.1007/s11065-018-9369-5
- Gonçalo AMG, Vieira-Coelho MA. The effects of trazodone on human cognition: a systematic review. Eur J Clin Pharmacol. 2021;77(11):1623–1637. doi: 10.1007/s00228-021-03161-6
- Wang J, Liu S, Zhao C, et al. Effects of trazodone on sleep quality and cognitive function in arteriosclerotic cerebral small vessel disease comorbid with chronic insomnia. Front Psychiatry. 2020;11:620. doi: 10.3389/fpsyt.2020.00620
- Burke SL, Hu T, Spadola CE, et al. Mild cognitive impairment: associations with sleep disturbance, apolipoprotein e4, and sleep medications. Sleep Med. 2018;52:168–176. doi: 10.1016/j.sleep.2018.09.001
- Alikhani M, Ebrahimi A, Farnia V, et al. Effects of treatment of sleep disorders on sleep, psychological and cognitive functioning and biomarkers in individuals with HIV/AIDS and under methadone maintenance therapy. J Psychiatr Res. 2020;130:260–272. doi: 10.1016/j.jpsychires.2020.07.043
- BrownlowJA, Miller KE, Gehrman PR. Insomnia and cognitive performance. Sleep Med Clin. 2020;15(1):71–76. doi: 10.1016/j.jsmc.2019.10.002
- Halliday M, Mallucci GR. Reply: Trazodone to change the risk of neurodegeneration: bedside to bench. Brain. 2017 Aug 1;140(8):e48. doi: 10.1093/brain/awx150 PMID: 28641370.
- Bolstad I, Toft H, Lien L, et al. Longitudinal determinants of insomnia among patients with alcohol use disorder. Alcohol. 2023;108:10–20. doi: 10.1016/j.alcohol.2022.11.002
- Wołyńczyk-Gmaj D, Jakubczyk A, Trucco EM, et al. Emotional dysregulation, anxiety symptoms and insomnia in individuals with alcohol use disorder. Int J Environ Res Public Health. 2022;19(5):2700. doi: 10.3390/ijerph19052700
- Zhabenko O, Krentzman AR, Robinson EA, et al. A longitudinal study of drinking and depression as predictors of insomnia in alcohol-dependent individuals. Subst Use Misuse. 2013;48(7):495–505. doi: 10.3109/10826084.2013.781182
- Miller MB, Donahue ML, Carey KB, et al. Insomnia treatment in the context of alcohol use disorder: a systematic review and meta-analysis. Drug Alcohol Depend. 2017;181:200–207. doi: 10.1016/j.drugalcdep.2017.09.029
- Hollister LE. Interactions between alcohol and benzodiazepines. Recent Dev Alcohol. 1990;8:233–239.
- Janiri L, Hadjichristos A, Buonanno A, et al. Adjuvant trazodone in the treatment of alcoholism: an open study. Alcohol Alcohol. 1998;33(4):362–365. doi: 10.1093/oxfordjournals.alcalc.a008405
- Di Nicola M, Pepe M, Panaccione I, et al. Update on pharmacological treatment for comorbid major depressive and alcohol use disorders: the role of extended-release trazodone. Curr Neuropharmacol. 2023;21(11):2195–2205. doi: 10.2174/1570159X21666230403080624
- Le Bon O, Murphy JR, Staner L, et al. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol. 2003;23(4):377–383. doi: 10.1097/01.jcp.0000085411.08426.d3
- Friedmann PD, Rose JS, Swift R, et al. Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2008;32(9):1652–1660. doi: 10.1111/j.1530-0277.2008.00742.x
- Kolla BP, Schneekloth TD, Biernacka JM, et al. Trazodone and alcohol relapse: a retrospective study following residential treatment. Am J Addict. 2011;20(6):525–529. doi: 10.1111/j.1521-0391.2011.00172.x
- Cooke JD, Cavender HM, Lima HK, et al. Antidepressants that inhibit both serotonin and norepinephrine reuptake impair long-term potentiation in hippocampus. Psychopharmacol (Berl). 2014;231(23):4429–4441. doi: 10.1007/s00213-014-3587-1
- Coin A, Noale M, Gareri P, et al. Clinical profile of trazodone users in a multisetting older population: data from the Italian GeroCovid Observational study. Eur Geriatr Med. 2023 Jun;14(3):465–476. doi: 10.1007/s41999-023-00790-1
- Gheysens T, Van Den Eede F, De Picker L. The risk of antidepressant-induced hyponatremia: a meta-analysis of antidepressant classes and compounds. Eur Psychiatry. 2024;67(1):e20. doi: 10.1192/j.eurpsy.2024.11
- Bixby AL, VandenBerg A, Bostwick JR. Clinical management of bleeding risk with antidepressants. Ann Pharmacother. 2019 Feb;53(2):186–194. doi: 10.1177/1060028018794005
- Kanner AM. Depression in neurological disorders: comorbidity or another clinical manifestation?. In: Strain JJ, Blumenfield M, editors. Depression as a systemic illness. (NY): Oxford Academic; 2018. doi: 10.1093/med/9780190603342.003.0007
- Werneck AL, Rosso AL, Vincent MB. The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson's disease. Arq Neuropsiquiatr. 2009;67(2B):407–412. doi: 10.1590/S0004-282X2009000300007
- Bhattacharjee S, Goldstone L, Ip Q, et al. Depression treatment among adults with multiple sclerosis and depression in ambulatory care settings in the United States. Mult Scler Int. 2017;2017:3175358. doi: 10.1155/2017/3175358
- Reding MJ, Orto LA, Winter SW. Antidepressant therapy after stroke. A double-blind trial. Arch Neurol. 1986;43(8):763–765. doi: 10.1001/archneur.1986.00520080011011
- La AL, Walsh CM, Neylan TC, et al. Long-term trazodone use and cognition: a potential therapeutic role for slow-wave sleep enhancers. J Alzheimers Dis. 2019;67(3):911–921. doi: 10.3233/JAD-181145
- Frasure-Smith N, Lespérance F. Reflections on depression as a cardiac risk factor. Psychosom Med. 2005;67(Suppl 1):S19–S25. doi: 10.1097/01.psy.0000162253.07959.db
- Huang KL, Su TP, Chen TJ, et al. Comorbidity of cardiovascular diseases with mood and anxiety disorder: a population based 4-year study. Psychiatry Clin Neurosci. 2009;63(3):401–409. doi: 10.1111/j.1440-1819.2009.01974.x
- Alvarez JW, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy. 2003;23(6):754–771. doi: 10.1592/phco.23.6.754.32185
- Lopes AA, Albert JM, Young EW, et al. Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int. 2004;66(5):2047–2053. doi: 10.1111/j.1523-1755.2004.00977.x
- Hedayati SS, Finkelstein FO. Epidemiology, diagnosis, and management of depression in patients with CKD. Am J Kidney Dis. 2009;54(4):741–752. doi: 10.1053/j.ajkd.2009.05.003
- Nagler EV, Webster AC, Vanholder R, et al. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012;27(10):3736–3745. doi: 10.1093/ndt/gfs295
- Egede LE, Ellis C. Diabetes and depression: global perspectives. Diabet Res Clin Pract. 2010;87(3):302–312. doi: 10.1016/j.diabres.2010.01.024
- Gagnon J, Lussier MT, MacGibbon B, et al. The impact of antidepressant therapy on glycemic control in Canadian primary care patients with diabetes mellitus. Front Nutr. 2018;5:47. doi: 10.3389/fnut.2018.00047
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR). Washington (DC): American Psychiatric Association Publishing; 2022. doi: 10.1176/appi.books.9780890425787
- Bear HA, Edbrooke-Childs J, Norton S, et al. Systematic review and meta-analysis: outcomes of routine specialist mental health care for young people with depression and/or anxiety. J Am Acad Child Adolesc Psychiatry. 2020;59(7):810–841. doi: 10.1016/j.jaac.2019.12.002
- Fava M, Hwang I, Rush AJ, et al. The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2009;15(8):856–867. doi: 10.1038/mp.2009.20
- Stringaris A, Maughan B, Copeland WS, et al. Irritable mood as a symptom of depression in youth: prevalence, developmental, and clinical correlates in the Great Smoky Mountains Study. J Am Acad Child Adolesc Psychiatry. 2013;52(8):831–840. doi: 10.1016/j.jaac.2013.05.017
- MacSweeney N, Louvet P, Zafar S, et al. Keeping up with the kids: the value of co-production in the study of irritability in youth depression and its underlying neural circuitry. Front Behav Neurosci. 2023;17:1124940. doi: 10.3389/fnbeh.2023.1124940
- Owens JA, Rosen CL, Mindell JA, et al. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey. Sleep Med. 2010;11(7):692–700. doi: 10.1016/j.sleep.2009.11.015
- Shamseddeen W, Clarke G, Keller MB, et al. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. J Child Adolesc Psychopharmacol. 2012;22(1):29–36. Erratum in: J Child Adolesc Psychopharmacol. 2019;29(7):573. doi: 10.1089/cap.2011.0027
- Boafo A, Greenham S, Sullivan M, et al. Medications for sleep disturbance in children and adolescents with depression: a survey of Canadian child and adolescent psychiatrists. Child Adolesc Psychiatr Ment Health. 2020;14(1):10. doi: 10.1186/s13034-020-00316-8
- Chen YL, Gau SS. Sleep problems and internet addiction among children and adolescents: a longitudinal study. J Sleep Res. 2016;25(4):458–465. doi: 10.1111/jsr.12388
- Lin YJ, Yen JY, Lin PC, et al. Circadian typologies and insomnia in individuals with internet gaming disorder comorbid with attention deficit/hyperactivity disorder. Sci Rep. 2023;13(1):12764. doi: 10.1038/s41598-023-39462-2
- Cuomo A, Ballerini A, Bruni AC, et al. Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice. Riv Psichiatr. 2019;54(4):137–149. doi: 10.1708/3202.31796
- Schifano N, Capogrosso P, Boeri L, et al. Medications mostly associated with priapism events: assessment of the 2015–2020 food and drug administration (FDA) pharmacovigilance database entries. Int J Impot Res. 2022;32:S16. doi: 10.1038/s41443-022-00583-3
- Pope HG Jr, Hudson JI. Antidepressant medication in the treatment of bulimia nervosa. Psychopathology. 1987;20(Suppl 1):123–129. doi: 10.1159/000284531
- Solyom L, Solyom C, Ledwidge B. Trazodone treatment of bulimia nervosa. J Clin Psychopharmacol. 1989;9(4):287–290. doi: 10.1097/00004714-198908000-00010
- Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292–297. doi: 10.1001/jamapsychiatry.2015.3278
- Pacheco-Colón I, Ramirez AR, Gonzalez R. Effects of adolescent cannabis use on motivation and depression: a systematic review. Curr Addict Rep. 2019;6(4):532–546. doi: 10.1007/s40429-019-00274-y
- Ek J, Jacobs W, Kaylor B, et al. Addiction and sleep disorders. Adv Exp Med Biol. 2021;1297:163–171. doi: 10.1007/978-3-030-61663-2_12
- Hawton K, CasañCasañAs I, Comabella C, et al. Risk factors for suicide in individuals with depression: a systematic review. J Affect Disord. 2013;147(1–3):17–28. doi: 10.1016/j.jad.2013.01.004
- Pompili M. Critical appraisal of major depression with suicidal ideation. Ann Gen Psychiatry. 2019;18(1):7. doi: 10.1186/s12991-019-0232-8
- Pompili M. On mental pain and suicide risk in modern psychiatry. Ann Gen Psychiatry. 2024;23(1):6. doi: 10.1186/s12991-024-00490-5
- Kessing LV. Severity of depressive episodes according to ICD-10: prediction of risk of relapse and suicide. Br J Psychiatry. 2004;184(2):153. doi: 10.1192/bjp.184.2.153
- Pompili M, Dell’osso BM, Rosso G, et al. Routine treatment pathways in a cohort of patients with major depression and suicidality in Italy: the ARIANNA observational study. Compr Psychiatry. 2023;127:152430. doi: 10.1016/j.comppsych.2023.152430
- Pompili M, Tondo L, Baldessarini RJ. Suicidal risk emerging during antidepressant treatment: recognition and intervention. Clin Neuropsychiatry. 2005;2:66–72.
- Fiorillo A, Carpiniello B, De Giorgi S, et al. Assessment and management of cognitive and psychosocial dysfunctions in patients with major depressive disorder: a clinical review. Front Psychiatry. 2018;9:493. doi: 10.3389/fpsyt.2018.00493
- Albert U, Tomasetti C, Marra C, et al. Treating depression in clinical practice: new insights on the multidisciplinary use of trazodone. Front Psychiatry. 2023 Aug 15;14:1207621. PMID: 37654988; PMCID: PMC10466041. doi: 10.3389/fpsyt.2023.1207621
- Buoli M, Rovera C, Pozzoli SM, et al. Is trazodone more effective than clomipramine in major depressed outpatients? A single-blind study with intravenous and oral administration. CNS Spectr. 2019;24(2):258–264. doi: 10.1017/S1092852917000773